The new indication adds to the 2021 approval of Susvimo (ranibizumab) for 'wet' or neovascular age-related macular ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
The US Food and Drug Administration (FDA) has approved Susvimo (ranibizumab injection) 100mg/mL for the treatment of diabetic ...
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness Susvimo is the first and only continuous delivery treatment ...
Genentech, a member of the Roche Group (RHHBY), announced that the U.S. Food and Drug Administration has approved Susvimo ...
Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87 million for projects in the ...
Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results